David Thompson
Corporate Officer/Principal chez INOZYME PHARMA, INC.
Provenance du réseau au premier degré de David Thompson
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 22 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à David Thompson via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Doctorate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Human Resources Officer | |
| MIT Sloan School of Management | College/University | Graduate Degree Masters Business Admin | |
| Stanford University | College/University | Undergraduate Degree Undergraduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Undergraduate Degree | |
Opna Bio SA
 Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Pharmaceuticals: Generic | Chief Executive Officer Founder | |
| Yale University | College/University | Corporate Officer/Principal Doctorate Degree | |
| IVERIC BIO, INC. | Pharmaceuticals: Generic | Director/Board Member Corporate Officer/Principal | |
| RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Chairman | |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Miscellaneous Commercial Services | Founder Director/Board Member | |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Medical Specialties | General Counsel | |
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Investment Managers | Private Equity Investor | |
| University of Saskatchewan | College/University | Doctorate Degree | |
| REATA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Biotechnology | Director/Board Member | |
| MORPHIC HOLDING, INC. | Pharmaceuticals: Major | Director/Board Member | |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Corporate Officer/Principal | |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ITERUM THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
| HYPERION THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
| The University of Chicago Booth School of Business | College/University | Masters Business Admin | |
Civitas Therapeutics, Inc.
 Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Biotechnology | Director/Board Member | |
Oculis SA
 Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
| DURATA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Biotechnology | Director/Board Member | |
Pivotal Bioventure Partners Investment Advisor LLC
 Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
Rallybio Holdings LLC
 Rallybio Holdings LLC Medical/Nursing ServicesHealth Services Rallybio Holdings LLC engages in the provision of healthcare services. The company is headquartered in New Haven, CT. | Medical/Nursing Services | Director/Board Member | |
| VAXCYTE, INC. | Biotechnology | Director/Board Member | |
Evommune, Inc.
 Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Plexium, Inc.
 Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
| RALLYBIO CORPORATION | Biotechnology | Director/Board Member | |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
| KALVISTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor | |
The Bioindustry Association
 The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Miscellaneous Commercial Services | Director/Board Member | |
| Scandinavian International Management Institute | College/University | Corporate Officer/Principal | |
ReNeuron Ltd.
 ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Biotechnology | Chief Executive Officer | |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 40 |
| Danemark | 5 |
| Royaume-Uni | 4 |
| Suisse | 3 |
| Canada | 2 |
Sectorielle
| Health Technology | 33 |
| Consumer Services | 9 |
| Commercial Services | 6 |
| Finance | 5 |
| Health Services | 2 |
Opérationnelle
| Director/Board Member | 119 |
| Corporate Officer/Principal | 45 |
| Independent Dir/Board Member | 37 |
| Undergraduate Degree | 22 |
| Private Equity Investor | 22 |
Relations les plus connectées
| Insiders | |
|---|---|
| Ed Mathers Mathers | 47 |
| Martin Edwards | 38 |
| Axel Bolte | 23 |
| Robert Hopfner | 20 |
| Ruchita Sinha | 18 |
| Reinaldo Diaz | 17 |
| Joseph P. Schlessinger | 16 |
| Lynne Sullivan | 16 |
| Kurt C. Gunter | 12 |
| Doug Treco Treco | 11 |
| Pedro Huertas | 10 |
| Sanjay Subramanian | 9 |
| Henric Bjarke | 8 |
| Soo-Jin Kim | 6 |
| Sarah Bhagat | 6 |
- Bourse
- Insiders
- David Thompson
- Connexions Sociétés